Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: A National Prescription registry study

Osteoporosis International

Volumn 24, Issue 1, 2013, Pages 321-328

  Abrahamsen, B ^a   Rubin, K H ^b   Eiken, P A ^c   Eastell, R ^d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adherence; Alendronate; Dementia; Fracture risk; Osteoporosis; Treatment failure

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID;

ADULT; AGED; AGING; ARTICLE; DEMENTIA; DRUG USE; FEMALE; FRACTURE; FRAGILITY FRACTURE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SEX DIFFERENCE; ULCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DEMENTIA; DENMARK; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; POLYPHARMACY; REGISTRIES; RISK FACTORS; SEX FACTORS; TREATMENT FAILURE; ULCER;

EID: 84872347532     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2184-6     Document Type: Article

References (31)

1. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P et al (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20:971-976
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
3. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
4. Hosking D, Alonso CG, Brandi ML (2009) Management of osteoporosis with PTH: treatment and prescription patterns in Europe. Current Med Res Opin 25:263-270. doi: 10.1185/03007990802645461
5. Clement FM, Harris A, Yong K, Lee KM, Manns BJ (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions. JAMA 302:1437-1443
6. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? JBMR. doi: 10.1002/jbmr.1582
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
8. Inderjeeth CA, Chan K, Kwan K, Lai M (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab. doi: 10.1007/s00774-012-0349-1
9. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130-1139
10. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94:3215-3225
11. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB (2011) Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Min Res: Off J Am Soc Bone Min Res 26:1662-1669. doi: 10.1002/jbmr.342
12. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1112
13. Rejnmark L, Abrahamsen B, Ejersted C, Hyldstrup L, Jensen J-EB, Madsen OR, et al. The Danish Bone Society Osteoporosis Diagnosis and Treatment Guideline. Aarhus. 2009 Available: http://www.dkms.dk/vejledning/11-glukokort. htm. Accessed 16 Jun 2012
14. Rizzoli R, Cooper C, Reginster J-Y, Abrahamsen B, Adachi JD, Brandi ML et al (2012) Antidepressant medications and osteoporosis. Bone. doi: 10.1016/j.bone.2012.05.018
15. Abrahamsen B, Brixen K (2009) Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk. Osteoporos Int 20:585-597
16. Eom C-S, Lee H-K, Ye S, Park SM, Cho K-H (2012) Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. JBMR 27:1186-1195. doi: 10.1002/jbmr.1554
17. Vestergaard P, Rejnmark L, Mosekilde L (2008) Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 82:92-101
18. Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153-161
19. Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE (2005) Association between Parkinson's disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 53:1559-1564
20. Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med
21. Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci B et al (2005) Prevalence of helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci 50:847-852
22. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon WM, Melton LJ III (1992) Risk of fractures in patients with pernicious anemia. J Bone Miner Res 7:573-579
23. Berry SD, Ngo L, Samelson EJ, Kiel DP (2010) Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 58:783-787. doi: 10.1111/j.1532-5415.2010.02767.x
24. Rejnmark L, Vestergaard P, Mosekilde L (2005) Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76:167-175
25. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L (2003) Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 33:41-50
26. Jamal SA, Hamilton CJ, Eastell R, Cummings SR (2011) Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA 305:800-807
27. Rejnmark L, Vestergaard P, Mosekilde L (2006) Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 21:1811-1817
28. Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG et al (2010) Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J Clin Endocrinol Metab 95:1924-1931. doi: 10.1210/jc.2009-2342
29. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T et al (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49:1271-1274
30. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
31. Laurs-van Geel TACM, Center JR, Geusens PP, Dinant G-J, Eisman JA (2010) Clinical fractures cluster in time after initial fracture. Maturitas 67:339-342. doi: 10.1016/j.maturitas.2010.09.002